Evidence map›Paper›PMID 42684586›Full record

ArticleCEN case reports2026

Durvalumab-associated nephrotic syndrome and organizing pneumonia: a case report.

Takashi Nawata, Masaki Shibuya, Maki Asami-Noyama, Noriko Uesugi, Motoaki Sano

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in CEN case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Takashi NawataDepartment of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, 755-8505, Yamaguchi, Japan. tnawata@yamaguchi-u.ac.jp.ORCID 0000-0003-0128-3463
Masaki ShibuyaDepartment of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, 755-8505, Yamaguchi, Japan.
Maki Asami-NoyamaDepartment of Respiratory Medicine and Infectious Disease, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Noriko UesugiDepartment of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Motoaki SanoDepartment of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, 755-8505, Yamaguchi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors have improved cancer prognosis, but are associated with immune-related adverse events, including rare renal complications. Here, we report the case of a 68-year-old Japanese man with unresectable advanced non-small cell lung cancer who developed nephrotic syndrome and organizing pneumonia associated with durvalumab therapy. The patient developed significant proteinuria during glucocorticoid treatment for organizing pneumonia. Renal biopsy led to a diagnosis of durvalumab-associated nephrotic syndrome. Histological examination revealed complex features, characterized by lesions resembling focal segmental glomerulosclerosis, marked foot process effacement and detachment, and prominent tubulointerstitial nephritis. Notably, his proteinuria improved following discontinuation of durvalumab and treatment with losartan potassium, dapagliflozin, and finerenone, without a substantial increase in the glucocorticoid dose. The clinical course highlights the heterogeneity of durvalumab-associated nephrotic syndrome.

Indexed as

Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungLung NeoplasmsNephrotic SyndromeOrganizing PneumoniaAgedHumansMaleProteinuriaAntibodies, MonoclonalAntineoplastic Agents, ImmunologicaldurvalumabDurvalumabImmune checkpoint inhibitorsImmune-related adverse eventsNephrotic syndromeOrganizing pneumonia

Identifiers

PMID42684586
PMCPMC13538327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.